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Risk of urothelial bladder cancer in Lynch syndrome is
increased, in particular among MSH2
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ABSTRACT
Background Colorectal, endometrial and upper urinary
tract tumours are characteristic for Lynch syndrome
(hereditary non-polyposis colon carcinoma, HNPCC). The
aim of the present study was to establish whether
carriers of mutations in mismatch repair genes MLH1,
MSH2 or MSH6 are at increased risk of urinary bladder
cancer.
Methods Carriers and first degree relatives of 95
families with a germline mutation in the MLH1 (n¼26),
MSH2 (n¼43), or MSH6 (n¼26) gene were
systematically questioned about the occurrence of
carcinoma. The cumulative risk of cancer occurring
before the age of 70 years (CR70) was compared to the
CR70 of the general Dutch population. Microsatellite
instability (MSI) testing and/or immunohistochemistry
(IHC) for mismatch repair proteins was performed on
bladder tumour tissue.
Results Bladder cancer was diagnosed in 21 patients
(90% men) from 19 Lynch syndrome families (2 MLH1,
15 MSH2, and 4 MSH6). CR70 for bladder cancer was
7.5% (95% CI 3.1% to 11.9%) for men and 1.0% (95% CI
0% to 2.4%) for women, resulting in relative risks for
mutation carriers and first degree relatives of 4.2 (95% CI
2.2 to 7.2) for men and 2.2 (95% CI 0.3 to 8.0) for
women. Men carrying an MSH2 mutation and their first
degree relatives were at highest risks: CR70 for bladder
and upper urinary tract cancer being 12.3% (95% CI
4.3% to 20.3%) and 5.9% (95% CI 0.7% to 11.1%).
Bladder cancer tissue was MSI positive in 6/7 tumours
and loss of IHC staining was found in 14/17 tumours,
indicating Lynch syndrome aetiology.
Conclusion Patients with Lynch syndrome carrying an
MSH2 mutation are at increased risk of urinary tract
cancer including bladder cancer. In these cases
surveillance should be considered.
INTRODUCTION
Lynch syndrome, previously called hereditary non-
polyposis colon carcinoma (HNPCC), is caused by
a germline mutation in one of the mismatch repair
(MMR) genes MLH1, MSH2, MSH6 and PMS2. It
results in a large increase in spontaneous muta-
tions and thus has a direct oncogenic effect.
Besides the high risk of developing colorectal
carcinomas of 10e80%, Lynch syndrome family
members are at increased risk of developing several
extra-colonic cancers and tumours at a relatively
young age: endometrial cancer, carcinomas of the
ovary, small bowel and biliary tract cancer, seba-
ceous gland tumours and urothelial carcinomas
(UC) of the upper urinary tract.1e10 The lifetime
risk of upper urinary tract cancer in Lynch
syndrome varies in different studies from
0.4e20%.1 2 6 9 11e18 Microsatellite instability
(MSI) is present in these urothelial carcinomas of
the upper urinary tract.19 20
A study based on the Swedish family cancer
database, quantifying the occurrence of UC in
families with at least four generations, showed that
families fulﬁlling the Bethesda criteria21 have an
increased risk of cancers in the ureter, but not in the
urinary bladder.18 It was concluded that in families
at risk for Lynch syndrome, UC of the bladder
occurs at a frequency comparable to that in the
general population. The study did not report results
which were stratiﬁed by type of mutation. On the
contrary, in a study by Geary et al, bladder cancer
was more common in MSH2 mutation families
than expected in the general population, the rela-
tive risk (RR) being 3.6 (p¼0.001).16 Cumulative
risks were not presented. In their study every case
of bladder cancer was accompanied by cancer of the
ureter in the family. For that reason, the authors
concluded that the risk of bladder cancer was
increased only in families with ureter cancer.
In addition to morphologic resemblance, sporadic
urothelial cell cancers of the renal pelvis, ureter and
bladder share the most important risk factors and
molecular genetic aberrations; it is therefore
remarkable that the risk of bladder cancer does not
appear to have increased in Lynch syndrome fami-
lies, while the risk of upper urinary tract cancer has.
The aim of the present study was to establish
whether patients with Lynch syndrome are at
increased risk of cancer of the urinary bladder.
PATIENTS AND METHODS
Patient population
From 95 Lynch syndrome families, we selected all
carriers of a germline mutation in the MSH2,
MLH1 or MSH6 gene, who had been seen and
registered at the Department of Human Genetics of
the Radboud University Nijmegen Medical Centre
between 1996 and November 2008, and all their
ﬁrst degree relativesda total of 627 men and 617
women. Information on mutation carriers and their
ﬁrst degree relatives was systematically collected by
postal questionnaires and telephone calls with
contact persons when data were outdated for more
than 1 year. In each family, one to six such persons
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were contacted in order to obtain up-to-date information on the
occurrence of carcinoma in mutation carriers and their ﬁrst
degree relatives. First degree relatives with MMR gene mutation
negative tests were excluded. All diagnoses of UC carcinoma
were veriﬁed and conﬁrmed by review of pathology reports or
medical reports.
Statistical analysis
We calculated follow-up time for each family member with the
date of birth as starting point until the dates of last contact,
death, or diagnosis of cancer, whichever came ﬁrst.
KaplaneMeier (KM) survival analyses were used to calculate the
cumulative risk (plus SE) of cancer until speciﬁc ages. We chose
the age of 70 as censuring age because the number of patients
being at risk after that age is small. SPSS version 16.0 was used
for KM analyses. For reference, we used life table cancer risk
estimates as reported by the Dutch Cancer Registry (http://
www.ikcnet.nl), based on cancer incidence and population
demographics in 2003.22 The life table risks of urinary tract
cancer are almost identical to those reported by SEER (Surveil-
lance Epidemiology and End Results) for whites in the USA
(http://seer.cancer.gov). Relative risks of cancer among speciﬁc
groups compared to the Dutch reference risks were deﬁned as
the ratio between observed and expected numbers of tumours
before the age of 70 years. Exact, 95% conﬁdence interval (CIs)
of the RRs were calculated using the publicly available OpenEpi
software (http://www.openepi.com).
Histology and molecular analysis
After written informed consent, histology reports and tissue
blocks of UC of the bladder, ureter or renal pelvis were collected.
Clinicopathological features of the urothelial cell cancers were
reviewed by two experienced pathologists using haematoxylin
and eosin (H&E) slides. The following parameters were scored:
(1) tumour differentiation according to the World Health
Organization 2004 grading system; (2) T stage (TNM 2002); (3)
growth pattern: papillary or solid; (4) presence of tumour inﬁl-
trating lymphocytes (TILs): absent, moderate or dense.
For MSI analysis, areas of the formalin ﬁxed and parafﬁn
embedded tissues containing either tumour cells (at least 30%)
or normal cells were marked and material from these areas was
isolated separately using a lysis buffer and a protein precipita-
tion solution (Purogene, Gentra systems, Minneapolis, Minne-
sota, USA). PCR of the markers D2S123, D5S346, D17S250,
BAT25, BAT26 and BAT40 was performed using standard
conditions in the presence of a ﬂuorescently labelled primer.
GeneScan analysis was performed on an ABI373A, ABI3100 or
ABI3700 apparatus (PE Biosystems, Foster City, California,
USA). A tumour was considered MSI positive when at least two
of these standard set of markers, or 30% of an extended set,
showed instability.23
Immunohistochemistry (IHC) was performed on formalin
ﬁxed, parafﬁn embedded tissues. Slides were stained with anti-
bodies against MLH1 (Pharmingen code: 51-1327gr), PMS2
(Pharmingen code: 556415), MSH2 (Oncogene Research Prod-
ucts code: NA26) and MSH6 (Transduction Laboratories code:
G70220). Staining patterns of MMR proteins were evaluated
using normal epithelial, stromal and inﬂammatory cells as
internal controls. Stained slides were scored as: (1) positived
that is, showing nuclear staining in at least some tumour cells;
(2) negativedthat is, no staining of the tumour with a positive
internal control; or (3) not assessabledthat is, insufﬁcient
technical quality to provide an unambiguous result despite
repeated assays.24 25 As a veriﬁcation ﬁve anonymous sporadic
cancers of the bladder were taken at random from the ﬁles of the
department of pathology.
RESULTS
Members of 95 Lynch syndrome families diagnosed by a germline
mutation inMLH1 (n¼26),MSH2 (n¼43) orMSH6 (n¼26) were
questioned by contact persons for occurrence of cancer such asUC
of the bladder, ureter or renal pelvis. The total cohort of 1244
Table 1 Life table cumulative risks of cancers before the age of 70 (%)
Sex Bladder Ureter and renal pelvis Urinary tract Colorectal Endometrial
MMR mutation carriers and first degree
relatives
M 75 (3.1e11.9) 3.7 (0.9e6.5) 11.2 (4.0e18.4) 43.8 (37.6e50.0)
n¼542 n¼13 n¼7 n¼20 n¼141
F 1.0 (0e2.4) 2.7 (0.3e5.1) 3.7 (0e7.5) 38.7 (32.5e44.9) 27.4 (21.4e33.4)
n¼519 n¼2 n¼5 n¼7 n¼112 n¼70
MLH1 mutation carriers and first degree
relatives
M 10.8 (0e25.2) 4.8 (0e14.0) 15.6 (0e39.2) 57.0 (45.2e68.8)
n¼138 n¼2 n¼1 n¼3 n¼51
F 0 2.4 (0e7.2) 2.4 (0e7.2) 50.4 (37.0e63.8) 19.5 (8.5e30.5)
n¼148 n¼0 n¼1 n¼1 n¼40 n¼12
MLH2 mutation carriers and first degree
relatives
M 12.3 (4.3e20.3) 5.9 (0.7e11.1) 18.2 (5.0e31.4) 43.5 (34.7e52.3)
n¼248 n¼10 n¼5 n¼15 n¼65
F 2.6 (0e3.8) 5.8 (0e11.6) 8.4 (0e15.4) 47.4 (36.8e58.0) 26.1 (16.9e35.3)
n¼213 n¼2 n¼4 n¼6 n¼51 n¼28
MLH6 mutation carriers and first degree
relatives
M 1.3 (0e3.9) 1.3 (0e3.9) 2.6 (0e7.8) 31.0 (20.0e42.0)
n¼156 n¼1 n¼1 n¼2 n¼25
F 0 0 0 22.1 (13.1e31.1) 32.7 (22.3e43.1)
n¼158 n¼0 n¼0 n¼0 n¼21 n¼30
Proven and obligate MMR mutation
carriers
M 16.4 (6.4e26.4) 91 (2.1e16.1) 25.5 (8.5e42.5) 70.1 (60.9e79.3)
n¼226 n¼12 n¼7 n¼19 n¼108
F 1.9 (0e4.9) 5.4 (0.2e10.6) 7.3 (0e15.5) 56.6 (47.4e65.8) 35.4 (26.8e44.0)
n¼232 n¼2 n¼5 n¼7 n¼89 n¼53
Dutch population M 1.79 0.10 1.89 2.70
F 0.45 0.04 0.49 2.14 1.05
F, female; M, male; MMR, mismatch repair.
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persons consisted of 406 proven mutation carriers (individuals
with a pathogenic mutation on germline mutation analysis) and
838ﬁrst degree relatives. The latter group consisted of 111 obligate
mutation carriers (concluded because of their position in the
pedigree in relation to relatives tested positive for amutation) and
727 persons at 50% risk to be mutation carriers. In 22 families, at
least one (n¼27) conﬁrmedmutation carrier or ﬁrst degree relative
of a mutation carrier was diagnosed with UC of the urinary
bladder, ureter or renal pelvis. In two additional MSH2 families,
the patient with UC of the bladder was not a ﬁrst but a second
degree relative of the mutation carrier diagnosed. Second degree
relatives were not included in the KM risk analysis but the two
second degree relatives with UC were included in the histopa-
thology study. UC of the bladder was diagnosed in 21 patients
from 19 Lynch syndrome families, the majority (71%) coming
fromMSH2 families (15MSH2, twoMLH1, and fourMSH6); 19
out of 21 (90%)weremen. Two patients with bladder cancer were
at 50% risk of being an MSH2 mutation carrier, but could not be
tested. Bladder cancer was diagnosed at an average age of
60612 years (range 41e84 years), which is approximately
10 years younger than the average age of sporadic bladder cancer in
the Netherlands.
The cumulative risk of bladder cancer until the age of 70
(CR70) in all MMR mutation carriers and their ﬁrst degree
relatives was 7.5% (95% CI 3.1% to 11.9%) for men and 1.0%
(95% CI 0% to 2.4%) for women (table 1). The corresponding
CR70 for the Dutch population is 1.8% for men and 0.5% for
women. The RR for carriers of any MMR mutation, as
compared to the general Dutch population, was 4.2 (95% CI 2.2
to 7.2, p<0.001) for men and 2.2 (95% CI 0.3 to 8.0, p¼0.5) for
women (table 1). MSH2 mutation carriers and ﬁrst degree rela-
tives showed the highest risk of bladder cancer: CR70 is 12.3%
(95% CI 4.3% to 20.3%) in men and 2.6% (95% CI 0% to 3.9%)
for women. The RR of bladder cancer in carriers of an MSH2
mutation and their ﬁrst degree relatives, as compared to the
general Dutch population, was 7.0 (95% CI 3.4 to 13.0, p<0.001)
for men and 5.8 (95% CI 0.5 to 16.1, p¼0.15) for women. The
overall CR70 risk for urinary tract cancer, including the bladder,
in MSH2 mutation carriers and ﬁrst degree relatives was 18.2%
(95% CI 5.0% to 31.4%) in men and 8.4% (95% CI 0% to 15.4%)
in women (table 1).
Two or more primary urinary tract cancers, of which one was
in the bladder, were diagnosed in nine of all 21 patients with
bladder cancer; in six patients these two cancers were diagnosed
synchronously or within 1 year. The remaining three patients,
with a metachronous combination of bladder and upper urinary
tract cancer, had their bladder cancer diagnosed earlier in life
than the upper urinary tract cancer. Exclusive upper urinary
tract cancer was diagnosed in eight patients from seven Lynch
syndrome families, with 63% caused by MSH2 (ﬁve MSH2, two
MLH1, and one MSH6). The CR70 of colorectal cancer for
conﬁrmed MMR mutation carriers was 63.2% (95% CI 56.6% to
69.8%) and the CR70 of endometrial cancer was 35.4% (95% CI
26.8% to 44.0%) (table 1).
Bladder cancers from germline MSH2 mutation carriers were
tested for mismatch repair deﬁciency: MSI was present in
bladder tumour DNA from six out of seven cases, and IHC
staining of MSH2 protein was absent in nine out of 11 cases,
indicating mismatch repair deﬁciency (ﬁgure 2, table 2). Addi-
tionally, IHC staining of MLH1 or MSH6 proteins was absent in
ﬁve out of six bladder carcinomas fromMLH1 orMSH6 germline
mutation carriers, respectively (ﬁgure 1, table 2). Three bladder
tumours were identiﬁed having normal IHC staining and one
tumour was MSS. As a control, IHC of ﬁve sporadic bladder
carcinomas showed normal staining of all four MMR system
proteins. No typical histological characteristics were observed in
the bladder carcinomas when compared with sporadic bladder
carcinomas (table 2).
Figure 1 Absence of nuclear
immunohistochemical staining of MLH1
protein (A) and presence of MSH2
protein (B) in urothelial carcinomas (UC)
of the urinary bladder (original
magnifications, 2503) of a patient
carrying a germline MLH1 mutation.
Note in figure 1A the presence of
nuclear staining in normal mucosa and
absence in carcinoma.
Figure 2 Absence of nuclear
immunohistochemical staining of MSH2
protein (A) and presence of MLH1
protein (B) in urothelial cell carcinoma
of the urinary bladder (original
magnifications, 4003) of a patient
carrying a germline MSH2 mutation.
Observe the nuclear staining in stromal
cells as an internal control.
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DISCUSSION
This study indicates an increased risk of urothelial cancer of both
the urinary bladder and the upper urinary tract (ureter and renal
pelvis) in patients with Lynch syndrome carrying a germline
MSH2 mutation. Furthermore, this study indicates that cancer
of the urinary bladder, ureter and renal pelvis is also, though
rarely, associated with MSH6 or MLH1 mutations. A causal
relation between MSH2 deﬁciency and bladder cancer is likely:
in the ﬁrst place, because bladder cancers in these families often
show MSI and/or absence of IHC staining of the MSH2 protein,
just like upper urothelial tract cancer and colorectal cancer; in
the second place, because of the presence of two MSH2 muta-
tion families, each of which contained two ﬁrst degree family
members with bladder cancer, and with three of the bladder
cancers diagnosed under the age of 50 (as illustrated in ﬁgure 3).
It is interesting that especially MSH2 mutation carriers are at
increased risk of urothelial cancer, as observed in this cohort and
in previous studies.2 12 16 The diversity in the function of the
MSH2, MLH1 and MSH6 protein might be responsible for the
variation in cancer risk. Environmental factors (eg, smoking
status) may also affect the urologic tract cancer occurrence rates,
but we do not have the necessary information to determine if
this might contribute to the differences.
In eight out of 21 patients with bladder cancer, this was their
ﬁrst cancer diagnosis, whereas at this stage ﬁve of them developed
another Lynch syndrome associated cancer at an older age.
Therefore, early diagnosis of Lynch syndrome may prevent
development of a second primary cancer, especially colorectal
cancer (CRC) by regular colonoscopy with polypectomy.26 The
diagnosis of Lynch syndrome in healthy relatives may lead to
prevention or early detection of cancer, which improves the
prognosis.26 Thus bladder cancer, just like upper urothelial tract
cancer, can be added to the Bethesda criteria21 and the Amsterdam
II criteria,27 and lead to the clinical suspicion of Lynch syndrome.
The occurrence of bladder cancer can be used in family history
taking and molecular diagnostics to identify the families that are
at risk of Lynch syndrome.
Cumulative risks of colorectal and endometrial cancer are
within the ranges published by other studies.2e5 8 13 28 29 Bladder
cancer risk observed in our cohort was signiﬁcantly higher than
that observed in previous studies.6 9 12 16 18 These studies
differed from our study by: (1) type of risk that was calculated;
(2) by type of population; and (3) whether or not the type of
mutation was distinguished. The data from these studies are
given in table 3. Additionally the discrepancy in bladder cancer
risk between our study and other studies may result from our
systematic data collection approach (obtaining up-to-date
information). This led to the discovery of nine new cases of
bladder carcinoma, previously unrevealed with the standard
procedure of a clinical geneticist taking the family history.
Considering the high risk of urothelial tract cancer in MSH2
mutation carriers, a surveillance programme needs to be devel-
oped. At present various recommendations have been published.
The present European guidelines for families with an MMR
mutation include ultrasound and urinalysis every 1e2 years
with patients from the age of 30 to 35 only in cases where upper
urinary tract cancer runs in the family (two or more cases of
UC).11 The American guidelines include urinalysis with cytology
every 1e2 years with patients from the age of 25 to 35 for all
family members with Lynch syndrome.30 Watson et al proposed
(unspeciﬁed) surveillance of patients starting with the age of 50,
especially for families that carry mutations in MSH2.12
Although cytology is the superior marker in terms of speci-
ﬁcity,31 Myrhoy et al showed that the sensitivity of urine
cytology in diagnosing asymptomatic upper urinary tract cancer
in Lynch syndrome is approximately 30%. Therefore, cytology
only is not a proper method of surveillance.32 The most
important biomarker of urothelial cancer is macro- or micro-
scopically haematuria, which occurs in 85% of patients with
bladder cancer.33 Consequently, Koornstra et al recommend
annual surveillance for haematuria, by urinary dipstick, of all
patients with Lynch syndrome, beginning at the age of 45 to
50.34 The recent use of sensitive transducers has improved
imaging of the upper urinary tract and bladder by
Figure 3 Pedigree of a Lynch
syndrome family with two MSH2
mutation carriers with urinary bladder
cancer. CRC, colorectal cancer.
Bladder ca 42 yr
Ureter ca 50 yr
Pyelum ca 51 yr
Endometrial ca 45 yr
CRC x2 52 yr
MSH2 mutation carrier
CRC 34 yr
Not tested
Gastric ca 39 yr
Not tested
Ovarian ca x2 40 yr
Not tested
Bladder ca 41 yr
CRC 49 yr
MSH2 mutation carrier
CRC 36 yr
Not tested
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ultrasonography. It was shown to be as accurate in the detection
of renal masses and bladder ﬁlling defects as intravenous urog-
raphy and computed tomography scanning.35
Further studies are needed to develop an optimum early
detection strategy concerning the appropriate interval, methods
to be used, and patient groups to be included. Until then, we
propose a combination of ultrasonography of the bladder and
upper urinary tract, urinary cytology and urine sediment
(erythrocytes) every 1e2 years. We recommend a surveillance
programme for UC of the bladder and upper urinary tract for all
MSH2mutation carriers starting at the age of 40, which is based
on the youngest Lynch syndrome patient with bladder cancer
reported in the literature (age 40) and observed in our study
(age 41).36 The top age limit of surveillance for UC can be similar
to that of surveillance for colorectal cancer. Surveillance should
not be limited to families with a history of UC, because in our
study clustering of urinary tract cancer was only observed in ﬁve
families, while 19 patients had a negative family history of
urinary tract cancer.
In conclusion, our data suggest that in addition to upper
urinary tract cancer, urothelial cancer of the urinary bladder is
part of the Lynch syndrome tumour spectrum. Carriers of an
MSH2mutation are particularly at increased risk of urinary tract
cancer including cancer of the bladder. In these cases we consider
surveillance necessary.
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Recommendations for urothelial carcinomas surveillance
in Lynch syndrome
1. Surveillance with a combination of ultrasound of the bladder
and upper urinary tract, urinary cytology and sediment.
2. In every MSH2 mutation carrier
3. From age 40 and up
4. Performed every 1e2 years
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